Skip to main content
Top

05-07-2020 | Insulin aspart | News

approvalsWatch

Insulin aspart biosimilar gets EMA nod

Author: Eleanor McDermid

print
PRINT
insite
SEARCH

medwireNews: A biosimilar of the rapid-acting insulin aspart has received a positive opinion from the EMA.

The biosimilar (insulin aspart Sanofi) is approved for use in adults and children aged at least 1 year with diabetes, based on the findings of the GEMELLI 1 trial.

The open-label GEMELLI 1 study involved 497 adults with type 1 diabetes and 100 with type 2 diabetes, who were randomly assigned to receive insulin aspart (NovoRapid/NovoLog) or the biosimilar. The biosimilar proved noninferior when used for a period of 6 months, and the two insulin analogs had similar safety profiles.

medwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature Group

print
PRINT

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »